Angiopoietin-2 axis inhibitors: Current status and future considerations for cancer therapy

Current Angiogenesis

Volumn 2, Issue 1, 2013, Pages 2-12

  Molnar, Nikolett ^a   Siemann, Dietmar W ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiopoietin 2; Anti angiogenic agent; Cancer therapy; Tie2; Tumor vasculature; Vascular targeted therapy

Indexed keywords

ACTP 1003; AMG 780; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ARGININE; ARRY 614; AXITINIB; CEP 11981; COMBRETASTATIN; CVX 060; GLUTAMINE; HUMAN MONOCLONAL ANTIBODY; NESVACUMAB; PLERIXAFOR; PROLINE; REACTIVE OXYGEN METABOLITE; TIE 1 RECEPTOR; TREBANANIB; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ADVANCED CANCER; AMINO ACID SEQUENCE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ASTROCYTOMA; BLOOD VESSEL PERMEABILITY; BRAIN METASTASIS; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CELL INTERACTION; CELLULAR SECRETION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EVALUATION; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; DNA DAMAGE; DRUG EFFICACY; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HUMAN; INFLAMMATORY CELL; INTRACELLULAR SIGNALING; IONIZING RADIATION; KIDNEY FUNCTION; LIGAND BINDING; LIVER CELL CARCINOMA; LONG TERM EXPOSURE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MELANOMA; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; MULTIPLE ORGAN FAILURE; NASOPHARYNX CARCINOMA; NEUROENDOCRINE TUMOR; OLIGOMERIZATION; PELVIS CANCER; PERICYTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SEQUENCE HOMOLOGY; SMOOTH MUSCLE FIBER; SOFT TISSUE SARCOMA; SOLID TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR NECROSIS; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WEIBEL PALADE BODY; WOUND HEALING;

EID: 84952995475     PISSN: 22115528     EISSN: 22115536     Source Type: Journal    
DOI: 10.2174/221155281120100006     Document Type: Review

References (127)

1. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002; 282: C947-70.
2. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-86.
3. Nowak-Sliwinska P. Anti-angiogenic treatment for exudative agerelated macular degeneration: new strategies are underway. Curr Angiogen 2012; 1: 318-34.
4. Kim LA, D'Amore PA. Neovascular age-related macular degeneration: past, present, and future. Curr Angiogen 2012; 1: 105-14.
5. Angiogenesis inhibitors for cancer. January 3, 2013 [cited 2013 May 25]; Available from: http://www.angio.org/understanding/inhib.php
6. Liu J, Liu F, Waller DL, Wang J, Liu Q. Kinase inhibitors targeting anti-angiogenesis as anti-cancer therapies. Curr Angiogen 2012; 1: 335-46.
7. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 2004; 350: 2335-42.
8. Montero AJ, Escobar M, Lopes G, Gluck S, Vogel C. Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Onc Rep 2012; 14: 1-11.
9. Pollack A. F.D.A. revokes approval of Avastin for use as breast cancer drug. The New York Times 2011 November 19; Sect. B1.
10. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev 2008; 8: 592-603.
11. Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to antiangiogenic therapy and development of third-generation antiangiogenic drug candidates. Gen Cancer 2010; 1: 12-25.
12. Partanen J, Armstrong E, Makela TP, et al. A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol 1992; 12: 1698-707.
13. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161-69.
14. Schnurch H, Risau W. Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development 1993; 119: 957-68.
15. Valenzuela DM, Griffiths JA, Rojas J, et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans. Proc Natl Acad Sci USA 1999; 96: 1904-9.
16. Ribatti D, Vacca A, Presta M. The discovery of angiogenic factors: a historical review. Gen Pharmacol 2000; 35: 227-31.
17. Loughna S, Sato TN. Angiopoietin and Tie signaling pathways in vascular development. Matrix Biol 2001; 20: 319-25.
18. Thomas M, Augustin HG. The role of the Angiopoietins in vascular morphogenesis. Angiogenesis 2009; 12: 125-37.
19. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009; 10: 165-77.
20. D'Amico G, Korhonen EA, Waltari M, Saharinen P, Laakkonen P, Alitalo K. Loss of endothelial Tie1 receptor impairs lymphatic vessel development-brief report. Arterioscler Thromb Vasc Biol 2010; 30: 207-9.
21. Song SH, Kim KL, Lee KA, Suh W. Tie1 regulates the Tie2 agonistic role of angiopoietin-2 in human lymphatic endothelial cells. Biochem Biophys Res Comm 2012; 419: 281-6.
22. Yuan HT, Venkatesha S, Chan B, et al. Activation of the orphan endothelial receptor Tie1 modifies Tie2-mediated intracellular signaling and cell survival. FASEB J 2007; 21: 3171-83.
23. Davis S, Papadopoulos N, Aldrich TH, et al. Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering. Nat Struct Biol 2003; 10: 38-44.
24. Procopio WN, Pelavin PI, Lee WM, Yeilding NM. Angiopoietin-1 and-2 coiled coil domains mediate distinct homo-oligomerization patterns, but fibrinogen-like domains mediate ligand activity. J Biol Chem 1999; 274: 30196-201.
25. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55-60.
26. Fiedler U, Krissl T, Koidl S, et al. Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem 2003; 278: 1721-7.
27. Barton WA, Tzvetkova D, Nikolov DB. Structure of the angiopoietin-2 receptor binding domain and identification of surfaces involved in Tie2 recognition. Structure 2005; 13: 825-32.
28. Saharinen P, Alitalo K. The yin, the yang, and the angiopoietin-1. J Clin Invest 2011; 121: 2157-9.
29. Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002; 3: 411-23.
30. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87: 1171-80.
31. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nat 1995; 376: 70-4.
32. Hayashi M, Majumdar A, Li X, et al. VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation. Nat Comm 2013; 4: 1672-87.
33. Gavard J, Patel V, Gutkind JS. Angiopoietin-1 prevents VEGFinduced endothelial permeability by sequestering Src through mDia. Dev Cell 2008; 14: 25-36.
34. Eklund L, Saharinen P. Angiopoietin signaling in the vasculature. Exp Cell Res 2013; 319: 1271-80.
35. Venneri MA, De Palma M, Ponzoni M, et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007; 109: 5276-85.
36. Mazzieri R, Pucci F, Moi D, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011; 19: 512-26.
37. Seegar TC, Eller B, Tzvetkova-Robev D, et al. Tie1-Tie2 interactions mediate functional differences between angiopoietin ligands. Mol Cell 2010; 37: 643-55.
38. Kim KL, Shin IS, Kim JM, et al. Interaction between Tie receptors modulates angiogenic activity of angiopoietin2 in endothelial progenitor cells. Cardiovas Res 2006; 72: 394-402.
39. Yu X, Seegar TC, Dalton AC, et al. Structural basis for angiopoietin-1-mediated signaling initiation. Proc Natl Acad Sci USA 2013; 110: 7205-10.
40. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-8.
41. Korff T, Kimmina S, Martiny-Baron G, Augustin HG. Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness. FASEB J 2001; 15: 447-57.
42. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immun 2006; 27: 552-8.
43. Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006; 12: 235-9.
44. Tsigkos S, Zhou Z, Kotanidou A, et al. Regulation of Ang2 release by PTEN/PI3-kinase/Akt in lung microvascular endothelial cells. J Cell Phys 2006; 207: 506-11.
45. Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004; 103: 4150-6.
46. Dixit M, Bess E, Fisslthaler B, et al. Shear stress-induced activation of the AMP-activated protein kinase regulates FoxO1a and angiopoietin-2 in endothelial cells. Cardiovasc Res 2008; 77: 160-8.
47. Huang YQ, Li JJ, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of angiopoietin-2 from human umbilical vein endothelial cells. Blood 2002; 99: 1646-50.
48. Gallagher DC, Parikh SM, Balonov K, et al. Circulating angiopoietin 2 correlates with mortality in a surgical population with acute lung injury/adult respiratory distress syndrome. Shock 2008; 29: 656-61.
49. David S, Mukherjee A, Ghosh CC, et al. Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis. Crit Care Med 2012; 40: 3034-41.
50. van der Heijden M, Pickkers P, van Nieuw Amerongen GP, et al. Circulating angiopoietin-2 levels in the course of septic shock: relation with fluid balance, pulmonary dysfunction and mortality. Int Care Med 2009; 35: 1567-74.
51. Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem 2000; 7: 1163-70.
52. Jang C, Koh YJ, Lim NK et al. Angiopoietin-2 exocytosis is stimulated by sphingosine-1-phosphate in human blood and lymphatic endothelial cells. Arterioscler Thromb Vasc Biol 2009; 29: 401-7.
53. Diaz-Sanchez A, Matilla A, Nunez O, et al. Serum angiopoietin-2 level as a predictor of tumor invasiveness in patients with hepatocellular carcinoma. Scand J Gastro 2013; 48: 334-43.
54. Mitsuhashi N, Shimizu H, Ohtsuka M, et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology 2003; 37: 1105-13.
55. Moon WS, Park HS, Yu KH, et al. Expression of angiopoietin 1, 2 and their common receptor Tie2 in human gastric carcinoma: implication for angiogenesis. J Korean Med Sci 2006; 21: 272-8.
56. Zagzag D, Hooper A, Friedlander DR, et al. In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis. Exp Neurol 1999; 159: 391-400.
57. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998; 153: 1459-66.
58. Engin H, Ustundag Y, Tekin IO, Gokmen A, Ertop S, Ilikhan SU. Plasma concentrations of angiopoietin-1, angiopoietin-2 and Tie-2 in colon cancer. Eur Cyt Net 2012; 23: 68-71.
59. Goede V, Coutelle O, Neuneier J, et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 2010; 103: 1407-14.
60. Tsutsui S, Inoue H, Yasuda K, et al. Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density. Breast Cancer Res Treat 2006; 98: 261-6.
61. Lind AJ, Wikstrom P, Granfors T, Egevad L, Stattin P, Bergh A. Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostrate 2005; 62: 394-9.
62. Sugimachi K, Tanaka S, Taguchi K, Aishima S, Shimada M, Tsuneyoshi M. Angiopoietin switching regulates angiogenesis and progression of human hepatocellular carcinoma. J Clin Pathol 2003; 56: 854-60.
63. Bhaskar A, Gupta R, Sreenivas V, et al. Synergistic effect of vascular endothelial growth factor and angiopoietin-2 on progression free survival in multiple myeloma. Leuk Res 2013; 37: 410-5.
64. Helfrich I, Edler L, Sucker A, et al. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 2009; 15: 1384-92.
65. Detjen KM, Rieke S, Deters A, et al. Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Clin Cancer Res 2010; 16: 420-9.
66. Yamakawa M, Liu LX, Belanger AJ, et al. Expression of angiopoietins in renal epithelial and clear cell carcinoma cells: regulation by hypoxia and participation in angiogenesis. Am J Phys 2004; 287: F649-57.
67. Currie MJ, Gunningham SP, Turner K, et al. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. J Pathol 2002; 198: 502-10.
68. Xia Y, Lu RN, Li J. Angiogenic factors in chronic lymphocytic leukemia. Leuk Res 2012; 36: 1211-7.
69. Ahmad SA, Liu W, Jung YD, et al. The effects of angiopoietin-1 and-2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 2001; 61: 1255-9.
70. Imanishi Y, Hu B, Jarzynka MJ, et al. Angiopoietin-2 stimulates breast cancer metastasis through the alpha(5)beta(1) integrinmediated pathway. Cancer Res 2007; 67: 4254-63.
71. Tanaka F, Ishikawa S, Yanagihara K, et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 2002; 62: 7124-9.
72. Bach F, Uddin FJ, Burke D. Angiopoietins in malignancy. Eur J Surg Oncol 2007; 33: 7-15.
73. Sie M, Wagemakers M, Molema G, Mooij JJ, de Bont ES, den Dunnen WF. The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme. J Neurosurg 2009; 110: 147-55.
74. Park JH, Park KJ, Kim YS, et al. Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 2007; 132: 200-6.
75. Carlson TR, Feng Y, Maisonpierre PC, Mrksich M, Morla AO. Direct cell adhesion to the angiopoietins mediated by integrins. J Biol Chem 2001; 276: 26516-25.
76. Hu B, Jarzynka MJ, Guo P, Imanishi Y, Schlaepfer DD, Cheng SY. Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway. Cancer Res 2006; 66: 775-83.
77. De Palma M, Naldini L. Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. Clin Cancer Res 2011; 17: 5226-32.
78. Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res. 2009; 15: 5020-5.
79. Hudkins RL, Becknell NC, Zulli AL, et al. Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/ tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5, 4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent. J Med Chem 2012; 55: 903-13.
80. [cited 2013 May 20]; Available from: www.clinicaltrials.gov
81. Burd A, Whiteside M, Castillo J, Kunkel A, Fattaey A. ACTB-1003-a unique oral pan FGFR and PI3K pathway inhibitor with divergent modes of action. Molecular targeted therapies preclinical Poster 141 2010.
82. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011; 129: 245-55.
83. Zhang Y, Guessous F, Kofman A, Schiff D, Abounader R. XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs. 2010; 13: 112-21.
84. Beaulieu N, Dupont I, Bonfils C, et al. MGCD265, an Orally Active Met/VEGFR Multitargeted Kinase Inhibitor in Phase II Clinical Development, Potently Inhibits Clinically Relevant Met Mutants. 2011. Available from methylgene. solocom. biz/files/2011/09/poster106. pdf.
85. Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res 2013; 73: 1649-57.
86. Coxon A, Bready J, Min H, et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 2010; 9: 2641-51.
87. Thomas M, Kienast Y, Scheuer W, et al. A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and antiangiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors. PloS ONE 2013; 8: e54923.
88. Mita AC, Takimoto CH, Mita M, et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010; 16: 3044-56.
89. Elice F, Rodeghiero F. Side effects of anti-angiogenic drugs. Thromb Res 2012; 129 (Suppl 1): S50-3.
90. Daly C, Eichten A, Castanaro C, et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 2013; 73: 108-18.
91. Suri C, McClain J, Thurston G, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998; 282: 468-71.
92. Doppalapudi VR, Huang J, Liu D, et al. Chemical generation of bispecific antibodies. Proc Natl Acad Sci USA 2010; 107: 22611-6.
93. Leow CC, Coffman K, Inigo I, et al. MEDI3617, a human antiangiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models. Int J Oncol 2012; 40: 1321-30.
94. Giaccia AJ, Hall EJ. Cell Survival Curves. In: Giaccia AJ, Hall EJ, Eds. Radiobiology for the Radiologist. 6 Ed. Philadelphia PA: Lippincott Williams and Wilkins 2006; 30-46.
95. Giaccia AJ, Hall EJ. Oxygen Effect and Reoxygenation. In: Giaccia AJ, Hall EJ, Eds. Radiobiology for the Radiologist. 6 Ed. Philadelphia, PA: Lippincott Williams and Wilkins 2006; 85-105.
96. Bristow RG, Hill RP. Molecular and Cellular Basis of Radiotherapy. In: Tannock IF HR, Bristow RG, and Harrington L, Eds. The Basic Science of Oncology. 4 Ed: McGraw-Hill Medical Publishing Division 2005; 261-88.
97. Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev 2008; 8: 180-92.
98. Chapman JD, Whitmore GF. Chemical Modifiers of Cancer Treatment. Intl J Radiat Oncol Biol Phys 1984; 10: 1161-813.
99. Overgaard J, Horsman MR. Modification of Hypoxia Induced Radioresistance in Tumors by the Use of Oxygen and Sensitizers. Semin Radiat Oncol 1996; 6: 10-21.
100. Coleman CN. Hypoxic Cell Radiosensitizers: Expectations and Progress in Drug Development. Intl J Radiat Oncol Biol Phys 1985; 11: 323-9.
101. Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 2011; 37: 63-74.
102. Horsman MR, Siemann DW. Pathophysiological Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies. Cancer Res 2006; 66: 11520-39.
103. Dings RP, Loren M, Heun H, et al. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007; 13: 3395-402.
104. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract 2006; 3: 24-40.
105. Siemann DW. Tumor vasculature: a target for anticancer therapies. In: Siemann DW, ed. Vascular Targeted Therapies in Oncology. West Sussex, United Kingdom: Wiley Ltd. 2006; 1-8.
106. Vogel J, Camphausen K. Angiogenesis inhibitors and radiation in multimodality cancer therapy: preclinical and clinical studies. Curr Angiogen 2012; 1: 157-67.
107. Schmidt B, Lee HJ, Ryeom S, Yoon SS. Combining Bevacizumab with radiation or chemoradiation for solid tumors: a review of the scientific rationale, and clinical trials. Curr Angiogen 2012; 1: 169-79.
108. Senan S, Smit EF. Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 2007; 12(4): 65-77.
109. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
110. Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001; 61: 2413-9.
111. Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003; 63: 4009-16.
112. Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005; 11: 416-20.
113. Siemann DW, Shi W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 2004; 60: 1233-40.
114. Chen F, Feng Y, Zheng K, et al. Enhanced antitumor efficacy of a vascular disrupting agent combined with an antiangiogenic in a rat liver tumor model evaluated by multiparametric MRI. PloS One 2012; 7: e41140.
115. Siemann DW, Shi W. Dual Targeting of tumor vasculature: combining Avastin and vascular disrupting agents (Ca4P or Oxi4503). Anticancer Res 2008; 28: 2027-32.
116. Shaked Y, Nathan P, Daenen LGM, Kerbel RS. Combining antiangiogenic drugs with vascular disrupting agents rationale and mechanisms of action. In: Meyer T, Ed. Vascular Disruptive Agents for the Treatment of Cancer. New York, NY: Springer Science+ Business Media LLC 2010; 117-34.
117. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004; 100: 2491-9.
118. Patterson DM, Zweifel M, Middleton MR, et al. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res 2012; 18: 1415-25.
119. Welford AF, Biziato D, Coffelt SB, et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 2011; 121: 1969-73.
120. Schadler SK, Ryeom SW. Regulation of tumor angiogenesis by the immune system. Curr Angiogen 2012; 1: 88-97.
121. De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immun 2007; 28: 519-24.
122. Solinas G, Germano G, Mantovani A, Allavena P. Tumorassociated macrophages (TAM) as major players of the cancerrelated inflammation. J Leuk Biol 2009; 86: 1065-73.
123. Neal J, Wakelee H. AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. Curr Opin Mol Ther 2010; 12: 487-95.
124. Rini B, Szczylik C, Tannir NM, et al. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 2012; 118: 6152-61.
125. Oliner JD, Bready J, Nguyen L, et al. AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, inhibits angiogenesis in models of ocular neovascular diseases. Invest Ophthalm Vis Sci 2012; 53: 2170-80.
126. Robson EJ, Ghatage P. AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer. Exp Opin Invest Drugs 2011; 20: 297-304.
127. Doi T, Ohtsu A, Fuse N, et al. Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors. Cancer Chemoth Pharm 2013; 71: 227-35.